{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:50:17Z","timestamp":1754488217101,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"crossref","award":["AbbVie (US)"],"award-info":[{"award-number":["AbbVie (US)"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12325-019-01123-0","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T17:17:49Z","timestamp":1571851069000},"page":"3458-3470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of 8\u00a0Weeks of Glecaprevir\/Pibrentasvir in Treatment-Na\u00efve, HCV-Infected Patients with APRI\u2009\u2264\u20091 in a Single-Arm, Open-Label, Multicenter Study"],"prefix":"10.1007","volume":"36","author":[{"given":"Robert J.","family":"Fontana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Ankoma-Sey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bondin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Gabriela Pires","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Porcalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"1123_CR1","volume-title":"Global hepatitis report","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global hepatitis report. Geneva: World Health Organization; 2017."},{"key":"1123_CR2","volume-title":"Hepatitis C therapy in Germany: results from the german hepatitis C registry 4\u00a0years after approval of the new direct antiviral substances (DAAs)","author":"D Huppe","year":"2018","unstructured":"Huppe D, Serfert Y, Buggisch P, et al. Hepatitis C therapy in Germany: results from the german hepatitis C registry 4\u00a0years after approval of the new direct antiviral substances (DAAs). Wiesbaden: Viszeralmedizin; 2018."},{"issue":"3","key":"1123_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2036.2010.04370.x","volume":"32","author":"W Alazawi","year":"2010","unstructured":"Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32(3):344\u201355.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1123_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/cid\/civ860","volume":"62","author":"F Xu","year":"2016","unstructured":"Xu F, Moorman AC, Tong X, et al. All-Cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus. Clin Infect Dis. 2016;62(3):289\u201397.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1123_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637\u201348.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1123_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40261-015-0338-y","volume":"35","author":"A Messori","year":"2015","unstructured":"Messori A, Badiani B, Trippoli S. Achieving sustained virological response in hepatitis c reduces the long-term risk of hepatocellular carcinoma: an updated meta-analysis employing relative and absolute outcome measures. Clin Drug Investig. 2015;35(12):843\u201350.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"1123_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/jgh.13500","volume":"32","author":"Z Liu","year":"2017","unstructured":"Liu Z, Wei X, Chen T, Huang C, Liu H, Wang Y. Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: a systematic review with meta-analysis. J Gastroenterol Hepatol. 2017;32(3):548\u201357.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"1123_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/apt.13090","volume":"41","author":"Z Younossi","year":"2015","unstructured":"Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C\u2014the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41(6):497\u2013520.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1123_CR9","doi-asserted-by":"crossref","first-page":"238146831877663","DOI":"10.1177\/2381468318776634","volume":"3","author":"LE Cipriano","year":"2018","unstructured":"Cipriano LE, Goldhaber-Fiebert JD. Population health and cost-effectiveness implications of a \u201ctreat all\u201d recommendation for HCV: a review of the model-based evidence. MDM Policy Pract. 2018;3(1):2381468318776634.","journal-title":"MDM Policy Pract"},{"issue":"Suppl 1","key":"1123_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/liv.13668","volume":"38","author":"V Calvaruso","year":"2018","unstructured":"Calvaruso V, Petta S, Craxi A. Is global elimination of HCV realistic? Liver Int. 2018;38(Suppl 1):40\u20136.","journal-title":"Liver Int"},{"key":"1123_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"EASL","year":"2018","unstructured":"EASL. European Association for the Study of the Liver recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461\u2013511.","journal-title":"J Hepatol"},{"key":"1123_CR12","unstructured":"AASLD. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2018. https:\/\/www.hcvguidelines.org\/ . Accessed 27 Nov 2018."},{"key":"1123_CR13","volume-title":"Guidelines for the screening care and treatment of persons with chronic hepatitis C infection","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. Geneva: World Health Organization; 2018."},{"key":"1123_CR14","unstructured":"Australian recommendations for the management of hepatitis C virus infection: a consensus statement (September 2018). 2018. https:\/\/www.hepatologyassociation.com.au\/ . Accessed 22 Oct 2018."},{"issue":"22","key":"1123_CR15","doi-asserted-by":"publisher","first-page":"E677","DOI":"10.1503\/cmaj.170453","volume":"190","author":"H Shah","year":"2018","unstructured":"Shah H, Bilodeau M, Burak KW, et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190(22):E677\u201387.","journal-title":"CMAJ"},{"issue":"11","key":"1123_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","volume":"158","author":"R Chou","year":"2013","unstructured":"Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med. 2013;158(11):807\u201320.","journal-title":"Ann Intern Med"},{"issue":"S2","key":"1123_CR17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jvh.25_12922","volume":"25","author":"T Asselah","year":"2018","unstructured":"Asselah T, Lens S, Zadeikis N, et al. Analysis of AST to platelet ratio index (APRI) for determining eligibility for 8\u00a0weeks of glecaprevir\/pibrentasvir. J Viral Hepat. 2018;25(S2):19\u201320.","journal-title":"J Viral Hepat"},{"issue":"7","key":"1123_CR18","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/cid\/ciy220","volume":"67","author":"JK Rockstroh","year":"2018","unstructured":"Rockstroh JK, Lacombe K, Trinh R, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study. Clin Infect Dis. 2018;67(7):1010\u20137.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1123_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/cid\/ciz022","volume":"69","author":"Edward Gane","year":"2019","unstructured":"Gane E, Poordad F, Zadeikis N, et al. Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1\u20136 HCV infection and compensated liver disease. Clin Infect Dis. 2019. https:\/\/doi.org\/10.1093\/cid\/ciz022 .","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"1123_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"M Puoti","year":"2018","unstructured":"Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis. J Hepatol. 2018;69(2):293\u2013300.","journal-title":"J Hepatol"},{"key":"1123_CR21","unstructured":"MAVYRET (glecaprevir and pibrentasvir) [package insert]. North Chicago: Approved on August 2017. https:\/\/www.rxabbvie.com\/pdf\/mavyret_pi.pdf ."},{"key":"1123_CR22","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, et al. Real-life effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 201970(3):379\u201387."},{"issue":"S1","key":"1123_CR23","first-page":"364A","volume":"68","author":"J Wiegand","year":"2018","unstructured":"Wiegand J, Naumann U, Stoehr A, et al. Glecaprevir\/pibrentasvir for the treatment of patients with chronic hepatitis c virus infection: updated real-world data from the german hepatitis C-registry. Hepatology. 2018;68(S1):364A.","journal-title":"Hepatology"},{"key":"1123_CR24","unstructured":"MAVIRET (SmPC); AbbVie 2019\/MAVYRET (US package insert); AbbVie 2019."},{"issue":"11","key":"1123_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","volume":"14","author":"J Grebely","year":"2017","unstructured":"Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol. 2017;14(11):641\u201351.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"S1","key":"1123_CR26","doi-asserted-by":"publisher","first-page":"S280","DOI":"10.1016\/S0168-8278(18)30778-5","volume":"68","author":"D Back","year":"2018","unstructured":"Back D, Belperio P, Bondin M, et al. Integrated efficacy and safety of glecaprevir\/pibrentasvir in patients with psychiatric disorders. J Hepatol. 2018;68(S1):S280\u20131.","journal-title":"J Hepatol"},{"issue":"S1","key":"1123_CR27","first-page":"114A","volume":"66","author":"AS Brown","year":"2017","unstructured":"Brown AS, Welzel TM, Conway B, et al. Adherence to pangenotypic glecaprevir\/pibrentasvir treatment and SVR12 in HCV-infected patients: an integrated analysis of the phase 2\/3 clinical trial program. J Hepatol. 2017;66(S1):114A\u20135A.","journal-title":"J Hepatol"},{"key":"1123_CR28","doi-asserted-by":"crossref","unstructured":"Foster GR, Grebely J, Sherman KE, et al. Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1\u20136 and recent drug use. Hepatology. 2017;66(S1):636A\u2013637A.","DOI":"10.1016\/j.drugpo.2019.01.011"},{"issue":"8","key":"1123_CR29","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/lary.25821","volume":"126","author":"RJ Kamil","year":"2016","unstructured":"Kamil RJ, Jerschow E, Loftus PA, et al. Case-control study evaluating competing risk factors for angioedema in a high-risk population. Laryngoscope. 2016;126(8):1823\u201330.","journal-title":"Laryngoscope"},{"issue":"S1","key":"1123_CR30","first-page":"408A","volume":"68","author":"JJ Feld","year":"2018","unstructured":"Feld JJ, Sanchez Gonzalez Y, Pires dos Santos AG, Ethgen O. Clinical benefits, economic savings and faster time to HCV elimination with a simplified 8-week treatment and monitoring program in chronic F0-F3 naive patients in the US. Hepatology. 2018;68(S1):408A\u2013409A.","journal-title":"Hepatology"},{"issue":"S1","key":"1123_CR31","first-page":"425A","volume":"68","author":"RS Brown Jr","year":"2018","unstructured":"Brown RS Jr, Hezode C, Wang S, et al. Preliminary efficacy and safety of 8-week glecaprevir\/pibrentasvir in patients with HCV genotypes 1\u20136 infection and compensated cirrhosis: the EXPEDITION-8 study. Hepatology. 2018;68(S1):425A\u20136A.","journal-title":"Hepatology"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01123-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01123-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01123-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:59:52Z","timestamp":1695344392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01123-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01123-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}